Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$44.83 USD
-0.04 (-0.09%)
Updated Nov 4, 2024 03:59 PM ET
After-Market: $44.80 +0.02 (0.04%) 4:50 PM ET
3-Hold of 5 3
C Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 44.83 -0.04(-0.09%)
Will AGIO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
Other News for AGIO
Bank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)
Agios Pharmaceuticals price target raised to $53 from $51 at Scotiabank
Agios Pharmaceuticals price target raised by $2 at Scotiabank, here's why
Agios Pharma (AGIO) Gets a Buy from Scotiabank
Agios Pharma (AGIO) Receives a Buy from RBC Capital